^
    1year
    Cancer stemness kinase inhibitor amcasertib: a promising therapeutic agent in ovarian cancer stem and cancer cell models with different genetic profiles. (PubMed, Med Oncol)
    Furthermore, the suppression of Nanog-mediated stem cell-like features by Amcasertib was particularly pronounced in ER-negative ovarian cancer and cancer stem cells, highlighting its high anticancer efficacy in this subgroup. These results suggest that Amcasertib holds promise as a potential standalone or combination therapy agent for the treatment of ER-negative ovarian cancer.
    Journal
    |
    ER (Estrogen receptor) • NANOG (Nanog Homeobox)
    |
    ER negative
    |
    amcasertib (BBI-503)